Efficacy of Nebulised Tobramycin in Cystic Fibrosis Management: A Systematic Review

Main Article Content

G. T. Olowe

Abstract

Cystic Fibrosis (CF) is a progressive clinical condition associated with decreased functionality of glands that produce mucus, sweat, and intestinal secretions. CF is one of the most common recessive genetic diseases that affect all ethnic groups without any known identified cure, having variations in the severity of symptoms. In the treatment and management of CF, The choice and routes of administration of antibiotics taken is important in assessing effectiveness at different populations. In the light of this, current study was undertaken to determine the efficacy of Nebulised Tobramycin (NT) in the treatment of mild to moderate CF within 8years study period. Study was achieved by searching known repositories and electronic databases of various sources. Randomized Clinical Trials (RCTs) that compares patients treated on NT and placebo were selected, including six (6) RCTs comprising 609 participants to the review. Study noticed significant clinical and methodological heterogeneity among trials with NT, varying over a total of 8years study period. Also, there were recorded evidences of improvement in pulmonary function in most of the patients, following completion of the study. This review revealed inconclusive evidence in the efficacy of NT in the treatment of mild to moderate CF. It is thus clear, that long term use of NT in mild to moderate CF can provide sustained improvements in pulmonary functions.

Keywords:
Cystic fibrosis, nebulised tobramycin, randomized clinical trials

Article Details

How to Cite
Olowe, G. T. (2019). Efficacy of Nebulised Tobramycin in Cystic Fibrosis Management: A Systematic Review. Asian Journal of Research in Medical and Pharmaceutical Sciences, 7(2), 1-10. https://doi.org/10.9734/ajrimps/2019/v7i230116
Section
Original Research Article

References

Genetic Disease Foundation (GDF). Cystic Fibrosis [Internet]. GDF-Genetic Disease Foundation; 2010.

Available:http://www.geneticdiseasefoundation.org/genetic-diseases/

Accessed 2nd April, 2012

Rosalind L Smyth. Diagnosis and management of Cystic Fibrosis [Internet]. Group.bmj.com; 2005.

Available:http://ep.bmj.com/content/90/1/ep1.full.pdf

Accessed 4th April, 2012

Manama Bahrain. Implementation of cystic fibrosis services in developing countries [Internet]; 1995.

Available:http://www.cfww.org/docs/who/2002/implementation_cf_in_developing_countries_95-6.pdf

Accessed 5th April, 2012

Taurino AE, Peona V, Terzano C. Nebulised tobramycin in patients with chronic respiratory infections during clinical evolution of Wegener’s Granulomatosis [Internet]. European Review for Medical and Pharmacological Sciences. 2000;4: 131-138.

Available:http://www.europeanreview.org/pdf/183.pdf

Accessed 10th April, 2012

The Leeds Method of Management. Respiratory exacerbation and cystic fibrosis [Internet]. Leeds Regional Adults and Paediatric Cystic Fibrosis Units, St James university Hospital, Leeds, United Kingdom.

Available:http://www.cysticfibrosismedicine.com

Accessed 12th April, 2012

Diana Hubulashvili, Tania Ahuja. Antimicrobial therapy geared at pseudomonas aeruginosa for bronchiectasis [Internet]. The NYU Langone Internal medicine Blog-A Daily dose of Medicine; 2010.

Available:http://www.clinicalcorrelations.org/?p=2471

Accessed 16th April, 2012

Lori Alma. Newborn screening of cystic fibrosis [Internet]. About.Com; 2009.

Available:http://cysticfibrosis.about.com/od/diagnosis/a/newbornscreen.htm

Accessed 12th April, 2012

Robin Elise Weiss, LCCE. Cystic Fibrosis: Testing and prenatal diagnosis [Internet]. About.Com; 2012.

Available:http://pregnancy.about.com/od/babycomplications/a/cysticfibrosis.htm Accessed 10th April, 2012

Sterne ACJ, Rodrigues CL, Guedes NI. Does the efficacy of BCG decline with time since vaccination? [Internet]. The International Journal of Tuberculosis and Lung Disease. 1998;2:200-7.

Greenhalgh T. How to read a paper [Internet]. The Medline database. BMJ. 1997;315(7101):180-3.

Higgins JPT, Green S, Eds. Cochrane handbook for systematic review of Interventions [Internet]. John Wiley & Sons Ltd. Chichester; 2008.

Anonymous. Randomised controlled trials of single BCG, repeat BCG, or combined BCG and killed Mycobacteriume Leprae vaccine for prevention of leprosy and tuberculosis in Malawi [Internet]. Karonga prevention trial group. Lancet. 1996; 348(9019):17-24

Paul S, Eric S. A pilot study of the safety and efficacy of Tobramycin solution for inhalation in patients with bronchiectasis [Internet]; 2005.

Available:http://chestjournal.chestpubs.org/content/127/4/1420.full.pdf+html

Accessed 16th April, 2012

Chuchalin A, et al. A formulation of aerosolised tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: A double-blind, placebo-controlled, multicenter study. pubMed.gov. 2007;9(1):21-31.

Available:http://www.ncbi.nlm.nih.gov/pubmed/17536872

Accessed 14th April, 2012

Lenoir G, et al. Efficacy, Safety, and local pharmacokinetics of highly concentrated nebulised tobramycin in patients with cystic fibrosis colonised with pseudomonas aeruginosa. pubMed.gov. 2007; 9(1): 11-20.

Available:http://www.ncbi.nlm.nih.gov/pubmed/17536871

Accessed 13th April, 2012

Bonnie W, et al. Efficacy of aerosolised Tobramycin in patients with cystic fibrosis [Internet]. The New England Journal of Medicine. 1993;328:1740-1746.

Available:http://www.nejm.org/doi/full/10.1056/NEJM199306173282403

Accessed 10th April, 2012

Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER. Long-term efficacy of BCG Vaccine in Americans, Indians and Alaska Natives: A 60-year follow-up study. JAMA. 2004; 291(17):2086-91.

Available:http://www.ncbi.nlm.nih.gov/pubmed/15126436

Accessed 4th April, 2012

Hodson ME, Gallagher CG. New clinical evidence from the European tobramycin trial in cystic fibrosis [Internet]; 2002.

Available:http://www.sciencedirect.com/science/article/pii/S1569199302000048

Accessed 4th April, 2012

Petitti DB. Meta-analysis, decision –analysis and cost-effectiveness analysis: methods for quantitative synthesis in Medicine. 2nd Ed. Oxford University Press. Oxford; 2000.

Timothy D, et al. Treatment with tobramycin solution for inhalation reduces hospitalisation in young cystic fibrosis subjects with mild lung disease [Internet]. Wiley Online Library; 2004.

Available:http://onlinelibrary.wiley.com/doi/10.1002/ppul.20097/abstract.

Accessed 12th April, 2012.

Weisemann, HG et al. Placebo-controlled, double- blind, randomised study of aerosolised tobramycin for early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis [Internet]. 1998;25(2):88-92.

Available:http://www.ncbi.nlm.nih.gov/pubmed/9516091

Accessed 15th April, 2012

Ramagopal M, Lands LC. Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis [Internet]. 2000;29(5):366-70.

Available:http://www.ncbi.nlm.nih.gov/pubmed/10790248

Accessed 8th April, 2012

Deborah Leader. Definition of forced expiratory volume in one second (FEV-1) [Internet]. About.comCOPD; 2010.

Available:http://copd.about.com/od/glossaryofcopdterms/g/FEV1.htm

Accessed 6th April, 2012